Once For All to Acquire Nalanda Global
4.4.2024 09:00:00 EEST | Business Wire | Press release
Once For All (the “Company”), a European leader in supply chain compliance and sustainable sourcing solutions for the built environment, is excited to announce the acquisition of Nalanda Global (“Nalanda”), a leading supply chain risk and compliance management software platform in Spain.
The transaction extends Once For All’s European footprint into Spain and enhances the differentiated offering of its technology platform, adding scale and the ability to aid in providing a broader product suite to its customer base. Similar to Once For All, Nalanda operates a SaaS-based network that helps enable contractors in multiple industries to manage the compliance of sub-contractors in their supply chain. Nalanda also brings additional worker-level compliance and health & safety solutions to Once For All’s product suite.
Founded in 2000 by a group of preeminent Spanish construction companies, Nalanda is based in Madrid, Spain, and its international presence currently extends across more than ten countries in Europe and Latin America. Its solutions are used by large companies across a variety of engineering-related sectors including construction and facilities management. With a network of over 1,000 contractors and 45,000 sub-contractors as of December 2023, Nalanda has one of the largest digital communities of suppliers globally.
GTCR, a leading private equity firm, acquired Once For All in 2023 in partnership with Chief Executive David Hornsby. PSG Equity, a growth equity firm that partners with software and technology-enabled services companies, acquired a majority stake in Nalanda in 2021. As part of the transaction, which is expected to close in the coming weeks, the PSG funds will retain a minority stake in the combined business.
David Hornsby, Chief Executive of Once For All, said:
“Nalanda is a well-established provider with a product suite that strategically complements our own, and we are enthusiastic about combining our strengths as we continue to grow Once For All across Europe. We are excited to welcome the Nalanda team to Once For All and we look forward to working together.”
Juan Gil Rabadan, Founder and CEO of Nalanda, said:
“Nalanda has gone through a transformative journey over the last three years under PSG’s ownership. Through the investment in people and product, both organically and via M&A, we’ve established Nalanda as an industry leader in supply chain risk and compliance management in Spain, with a growing international presence. We are now thrilled to join Once For All as we share a vision for supporting the built environment globally. We look forward to partnering with the Once For All team and continuing to invest in innovating our technology and capabilities to serve our customers.”
Mark Anderson, Managing Director and Head of Technology, Media & Telecommunications at GTCR, said:
“The combination of Once for All and Nalanda helps position the business for future growth through a pan-European offering. The combined company provides a leading technology platform and differentiated suite of products to help address the critical supply chain and compliance needs of its customers. We are pleased to partner with the PSG team and look forward to the continued success of the business.”
Dany Rammal, Managing Director at PSG Equity, said:
“PSG is proud to have been part of the journey to create a leading Spain-based software champion. Nalanda’s success to date is a testament to Juan Gil Rabadan’s vision and his entire team’s dedication to scaling the Company’s solution into a comprehensive supply chain risk management and compliance offering. We are excited to be continuing the journey alongside GTCR, David Hornsby and the entire Once For All management team in support of the combined company’s growth journey.”
About Once For All
Once For All is a European leader in supply chain risk management and sustainable sourcing solutions for the construction industry. We help our customers source and track sales opportunities, manage risk and compliance, and provide tools to increase efficiency in their supply chains. Once For All has over 150,000 customers that use its single codebase SaaS solution to search, find and assess future business relationships based on skills, trades and ESG credentials. As a result, Once For All manages one of the largest proprietary ESG data sets in the world. Once For All has over 400 employees, is the market leader in UK and France and has operations in Belgium and Germany. For more information, please visit www.onceforall.com.
About Nalanda Global
Nalanda is a Spanish supplier risk and compliance management platform founded in 2000. It leverages intelligent cloud software to help connect companies and suppliers using a digital platform that enables the smooth exchange and verification of health and safety, due diligence, supplier validation, invoices, ESG and other business information, as well as providing solutions designed to ensure compliance with worker access, and working time. Nalanda operates in Spain, as well as in several European and Latin American countries. For more information, please visit www.nalandaglobal.com.
About GTCR
Founded in 1980, GTCR is a leading private equity firm that pioneered The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $25 billion in over 270 companies, and the firm currently manages $40 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.
About PSG Equity
PSG is a growth equity firm that partners with software and technology-enabled services companies to help them navigate transformational growth, capitalize on strategic opportunities and build strong teams. Having backed more than 135 companies and facilitated 479 add-on acquisitions, PSG brings extensive investment experience, deep expertise in software and technology, and a firm commitment to collaborating with management teams. Founded in 2014, PSG operates out of offices in Boston, Kansas City, London, Madrid, Paris and Tel-Aviv. To learn more about PSG, visit www.psgequity.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240403942729/en/
Contact information
Once For All
Arun Varma
arun.varma@onceforall.com
Nalanda
Goodwill Comunicación
Javier Herreros
jherreros@goodwill.es
GTCR
Andrew Johnson
Andrew.johnson@gtcr.com
PSG Equity
Prosek Partners
Matthieu Roussellier/Kate Pledger
Pro-psg@prosek.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari
IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release
IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi
Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release
Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas
Enhertu ® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 09:30:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across three phase 2 trials, including DESTINY-PanTumor02, DESTINY-Lung01 and DESTINY-CRC02. In DESTINY-PanTumor02, Enhertu demonstrated a confirmed objective response rate (ORR) of 52.3% (95% confidence interval [CI]: 42.6-6
Beerenberg Prevails in Patent Case Against Aspen Aerogels29.6.2026 08:00:00 EEST | Press release
The Korean Patent Court has invalidated three of Aspen Aerogels’ patents related to improved hydrophobic aerogel material. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260628192007/en/ Beerenberg delivers high-end insulation solutions built for performance, reliability, and long-term value. (Photo: Beerenberg) The ruling confirms the conclusion of the Intellectual Property Trial and Appeal Board (IPTAB) that the patents did not meet the necessary requirements for patentability. Beerenberg, which specializes in high-end insulation products, welcomes the court’s decision. “We are pleased that the case has now been concluded and that any uncertainty regarding the infringement claims has been removed,” says CEO Arild Apelthun. About Beerenberg Beerenberg has delivered cost-efficient solutions to a wide range of industrial enterprises for 49 years. The company is one of the leading suppliers of maintenance and modification serv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom